Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ramucirumab with Chemo for Advanced Gastric Cancer
NCT06169410Phase 4Recruiting
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ramucirumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms). Primary endpoint: Pathological Complete Response at 48 months. Started Dec 2023; status: recruiting.
02
Drugs
ramucirumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06169410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06169410.